Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors

NCT02709889 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02709889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02709889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Lead sponsor
AbbVie
Phase
Phase 1/2
Overall status
Terminated
Start date
September 23, 2016
Completion date
August 27, 2019
Enrollment
200 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, high grade gastroenteropancreatic neuroendocrine carcinoma, large-cell neuroendocrine carcinoma, malignant melanoma, medullary thyroid cancer, neuroendocrine prostate cancer, other neuroendocrine carcinoma, other solid tumors